← Shelf·NNMT (nicotinamide N-methyltransferase) inhibitor·XXIX.
5-Amino-1MQ.
A small-molecule compound (5-amino-1-methylquinolinium iodide) — not a peptide, technically a substrate-mimetic inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Characterized in the 2010s primarily by Alessio Neri and Robert Messing's group and other metabolic-disease labs.
NNMT is an enzyme your body expresses at elevated levels in adipose tissue in obesity, and it consumes cellular nicotinamide — a precursor to NAD+. Inhibiting NNMT is a research strategy to preserve nicotinamide pools for NAD+ biosynthesis. 5-Amino-1MQ is a synthetic inhibitor developed for that purpose.
Sold across the weight-loss peptide market with metabolic-benefit implications the primary literature has only rodent-scale evidence for. The mechanism (NNMT inhibition → preserved cellular nicotinamide → NAD+ pathway support) is intellectually coherent. Whether that mechanism translates to meaningful outcomes in humans at commonly-discussed injection doses is unstudied.
Straight talk
Straight talk: NNMT is a real enzyme; NNMT inhibition is a real metabolic strategy. 5-Amino-1MQ has published in vitro and rodent-model data supporting its effects on adipocyte metabolism. Human clinical trial data is absent. The compound is a research chemical with a coherent mechanistic story and no clinical evidence for the outcomes the marketing implies.
What the research studies
The literature, not a summary of it.
Foundational NNMT inhibitor development: Neri, Messing, and related groups. NNMT biology in obesity: Ulanovskaya (Cravatt group), Kraus. Journals: Nat Chem Biol, ACS Chem Biol, Cell Rep, Nature. Read the research yourself:
Recommended vendor · Amino Club
≥ 99% by HPLC on the current lot — ILS Laboratories (ISO/IEC 17025).
$32.49 during Fall Sale (was $49.99)
35% off applied automatically at checkout when you land through this link.
Related on the shelf